MTMichael Terrin

Michael Terrin

*This is an algorithmically generated author record based on publicly available information.

Michael Terrin has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time-restricted eating to entrain circadian rhythms, increase physiological responsiveness, and prevent stressor-induced frailty: A pilot randomized controlled trial

    by Amber S. Kleckner, Carin L. Clingan, Shalet James, Odessa Addison, Arif Hussain, Ian R. Kleckner, Supriya G. Mohile, Alice S. Ryan, Kaitlin Schotz, Michael Terrin, et al.

  • Comprehensive evaluation of plasma biomarkers in patients with abdominal aortic aneurysm using high-throughput, label-free quantitative proteomic profiling

    by Merry L. Lindsey, Emily I. Chen, Pushkar Shivam, Pius N. Nde, David Horn, Santosh Renuse, Amirmansoor Hakimi, B. Timothy Baxter, Michael Terrin, Jon S. Matsumura, et al.

    We describe methods for developing a high-throughput, label-free quantitative proteomics workflow integrated with physiological and clinical assessments to investigate cardiovascular disease mechanisms and identify potential biomarkers. This resource outlines a validated, longitudinal plasma proteomics pipeline—including data quality controls, statistical testing, and biological validation—applied to over 500 samples from the N-TA 3 CT trial, offering a reproducible framework for future biomarker discovery studies.


  • Open Access

    Hyperglycemia inhibits AAA expansion: examining the role of lysyl oxidase

    by Kathryn E. Jespersen, Wanfen Xiong, Lakshmi Santhanam, Michael Terrin, Jon Matsumura, John A. Curci, William Blackwelder, Clayton H. Brown, Marta Martinez Yus, B. Timothy Baxter

    AAA grows slower in patients affected by diabetes. This growth inhibition is lost when the enzyme lysyl oxidase (LOX) is blocked in diabetic mice. The predominant arterial isoform of LOX, LOX-like 2 (LOXL2), overlaps with type IV collagen in the outer media of murine aneurysm tissue. Circulating LOXL2 correlates inversely with AAA growth in patients. Type IV collagen cross-linking by LOXL2 may play a role in the AAA growth inhibition associated with diabetes.


  • Open Access

    Design and rationale of the CHILL phase II trial of hypothermia and neuromuscular blockade for acute respiratory distress syndrome

    by Carl B. Shanholtz, Michael L. Terrin, Thelma Harrington, Caleb Chan, Whittney Warren, Robert Walter, Faith Armstrong, Jeffrey Marshall, Rachel Scheraga, Abjihit Duggal, et al.


  • Open Access

    An mHealth Diabetes Intervention for Glucose Control: Health Care Utilization Analysis

    by Charlene C Quinn, Krystal K Swasey, Jamila M Torain, Michelle D Shardell, Michael L Terrin, Erik A Barr, Ann L Gruber-Baldini

    Background: Type 2 diabetes (T2D) is a major chronic condition requiring management through lifestyle changes and recommended health service visits. Mobile health (mHealth) is a promising tool to encourage self-management, but few studies have investigated the impact of mHealth on health care utilization. Objective: The objective of this analysis was to determine the change in 2-year health service utilization and whether utilization explained a 1.9% absolute decrease in glycated hemoglobin (HbA1c) over 1-year in the Mobile Diabetes Intervention Study (MDIS). Methods: We used commercial claims data from 2006 to 2010 linked to enrolled patients’ medical chart data in 26 primary care practices in Maryland, USA. Secondary claims data analyses were available for 56% (92/163) of participants. In the primary MDIS study, physician practices were recruited and randomized to usual care and 1 of 3 increasingly complex interventions. Patients followed physician randomization assignment. The main variables in the analysis included health service utilization by type of service and change in HbA1c. The claims data was aggregated into 12 categories of utilization to assess change in 2-year health service usage, comparing rates of usage pre- and posttrial. We also examined whether utilization explained the 1.9% decrease in HbA1c over 1 year in the MDIS cluster randomized clinical trial. Results: A significant group by time effect was observed in physician office visits, general practitioner visits, other outpatient services, prescription medications, and podiatrist visits. Physician office visits (P=.01) and general practitioner visits (P=.02) both decreased for all intervention groups during the study period, whereas prescription claims (P<.001) increased. The frequency of other outpatient services (P=.001) and podiatrist visits (P=.04) decreased for the control group and least complex intervention group but increased for the 2 most complex intervention groups. No significant effects of utilization were observed to explain the clinically significant change in HbA1c. Conclusions: Claims data analyses identified patterns of utilization relevant to mHealth interventions. Findings may encourage patients and health providers to discuss the utilization of treatment-recommended services, lab tests, and prescribed medications. Trial Registration: ClinicalTrials.gov NCT01107015; https://clinicaltrials.gov/ct2/show/NCT01107015 (Archived by Webcite at http://www.webcitation.org/72XgTaxIj)


  • Validated UHPLC–MS/MS Method for Quantification of Doxycycline in Abdominal Aortic Aneurysm Patients

    by Raghunadha Reddy Seelam, Michael Terrin, Hazem E Hassan

    Aim: There is a strong evidence that doxycycline can benefit abdominal aortic aneurysms patients because of its ability to inhibit matrix metalloproteinase enzymes. There is a need for a specific quantification method for doxycycline in these patients. We report herein the development and validation of a selective, specific, simple and rapid UHPLC–MS/MS method for doxycycline. Results: The assay was linear (r2 > 0.994) over a concentration range of 0.010–7.005 μg/ml. This validated method has good lower limit of quantification (LLOQ) (10 ng/ml), accuracies (89.1–103.4%), precision (≤7.0%) and extraction recoveries (95.8%). Doxycycline was stable during short- and long-term storage. Conclusion: The assay is reliable and has been successfully applied to serum samples obtained from the patients of N-TA3CT clinical study.


  • Open Access

    Mobile Diabetes Intervention Study of Patient Engagement and Impact on Blood Glucose: Mixed Methods Analysis

    by Charlene Connolly Quinn, Erin C Butler, Krystal K Swasey, Michelle D Shardell, Michael D Terrin, Erik A Barr, Ann L Gruber-Baldini

    Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.


  • Open Access

    The Impact of a Mobile Diabetes Health Intervention on Diabetes Distress and Depression Among Adults: Secondary Analysis of a Cluster Randomized Controlled Trial

    by Charlene C Quinn, Krystal K Swasey, J Christopher F Crabbe, Michelle D Shardell, Michael L Terrin, Erik A Barr, Ann L Gruber-Baldini

    Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.


  • Open Access

    Mobile Diabetes Intervention Study of Patient Engagement and Impact on Blood Glucose: Mixed Methods Analysis

    by Charlene Connolly Quinn, Erin C Butler, Krystal K Swasey, Michelle D Shardell, Michael D Terrin, Erik A Barr, Ann L Gruber-Baldini

    Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

  • Open Access

    Mobile Diabetes Intervention Study of Patient Engagement and Impact on Blood Glucose: Mixed Methods Analysis (Preprint)

    by Charlene Connolly Quinn, Erin C Butler, Krystal K Swasey, Michelle D Shardell, Michael D Terrin, Erik A Barr, Ann L Gruber-Baldini

    BACKGROUND Successful treatment of diabetes includes patient self-management behaviors to prevent or delay complications and comorbid diseases. On the basis of findings from large clinical trials and professional guidelines, diabetes education programs and health providers prescribe daily regimens of glucose monitoring, healthy eating, stress management, medication adherence, and physical activity. Consistent, long-term commitment to regimens is challenging. Mobile health is increasingly being used to assist patients with lifestyle changes and self-management behaviors between provider visits. The effectiveness of mobile health to improve diabetes outcomes depends on patient engagement with a technology, content, or interactions with providers. OBJECTIVES In the current analysis, we aimed to identify patient engagement themes in diabetes messaging with diabetes providers and determine if differences in engagement in the Mobile Diabetes Intervention Study (MDIS) influenced changes in glycated hemoglobin A1c (HbA1c) over a 1-year treatment period (1.9% absolute decrease in the parent study). METHODS In the primary MDIS study, 163 patients were enrolled into 1 of 3 mobile intervention groups or a usual care control group based on their physician cluster randomization assignment. The control group received care from their physicians as usual. Participants in each intervention group had access to a patient portal where they could record monitoring values for blood glucose, blood pressure, medication changes, or other self-management information while also assigned to varying levels of physician access to patient data. Intervention participants could choose to send and receive messages to assigned certified diabetes educators with questions or updates through the secure Web portal. For this secondary analysis, patient engagement was measured using qualitative methods to identify self-care themes in 4109 patient messages. Mixed methods were used to determine the impact of patient engagement on change in HbA1c over 1 year. RESULTS Self-care behavior themes that received the highest engagement for participants were glucose monitoring (75/107, 70.1%), medication management (71/107, 66.4%), and reducing risks (71/107, 66.4%). The average number of messages sent per patient were highest for glucose monitoring (9.2, SD 14.0) and healthy eating (6.9, SD 13.2). Compared to sending no messages, sending any messages about glucose monitoring (P=.03) or medication (P=.01) led to a decrease in HbA1c of 0.62 and 0.72 percentage points, respectively. Sending any messages about healthy eating, glucose monitoring, or medication combined led to a decrease in HbA1c of 0.54 percentage points compared to not sending messages in these themes (P=.045). CONCLUSIONS The findings from this study help validate the efficacy of the mobile diabetes intervention. The next step is to determine differences between patients who engage in mobile interventions and those who do not engage and identify methods to enhance patient engagement. CLINICALTRIAL ClinicalTrials.gov: NCT01107015; https://clinicaltrials.gov/ct2/show/NCT01107015 (Archived by WebCite at http://www.webcitation.org/6wh4ekP4R)